JP2014527083A - 治療用化合物 - Google Patents

治療用化合物 Download PDF

Info

Publication number
JP2014527083A
JP2014527083A JP2014530793A JP2014530793A JP2014527083A JP 2014527083 A JP2014527083 A JP 2014527083A JP 2014530793 A JP2014530793 A JP 2014530793A JP 2014530793 A JP2014530793 A JP 2014530793A JP 2014527083 A JP2014527083 A JP 2014527083A
Authority
JP
Japan
Prior art keywords
alkoxy
cyano
nitro
cancer
alkoxycarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014530793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527083A5 (enExample
Inventor
カール イー． ワグナー，
ピーター ダブリュー． ジュルツカ，
パメラ エー． マーシャル，
Original Assignee
アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー filed Critical アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー
Publication of JP2014527083A publication Critical patent/JP2014527083A/ja
Publication of JP2014527083A5 publication Critical patent/JP2014527083A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/62—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/68—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings containing halogen
    • C07C63/74—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings containing halogen having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2014530793A 2011-09-15 2012-09-13 治療用化合物 Pending JP2014527083A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161535311P 2011-09-15 2011-09-15
US61/535,311 2011-09-15
US201261681519P 2012-08-09 2012-08-09
US61/681,519 2012-08-09
PCT/US2012/055186 WO2013040227A2 (en) 2011-09-15 2012-09-13 Therapeutic compounds

Publications (2)

Publication Number Publication Date
JP2014527083A true JP2014527083A (ja) 2014-10-09
JP2014527083A5 JP2014527083A5 (enExample) 2015-08-20

Family

ID=47019147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014530793A Pending JP2014527083A (ja) 2011-09-15 2012-09-13 治療用化合物

Country Status (6)

Country Link
US (2) US9573906B2 (enExample)
EP (2) EP2755942A2 (enExample)
JP (1) JP2014527083A (enExample)
AU (1) AU2012308582B2 (enExample)
CA (1) CA2848540A1 (enExample)
WO (1) WO2013040227A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537140A (ja) * 2014-10-10 2017-12-14 ハイ フォース リサーチ リミテッド 蛍光合成レチノイド

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2755942A2 (en) 2011-09-15 2014-07-23 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Therapeutic compounds
ES2909884T3 (es) 2013-08-20 2022-05-10 Univ Washington Through Its Center For Commercialization Inhibidores nuevos y específicos de la hidroxilasa del ácido retinoico del citocromo P450 26
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
US9908856B2 (en) 2014-02-26 2018-03-06 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2016140978A1 (en) 2015-03-03 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2016140979A1 (en) 2015-03-03 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US20220259157A1 (en) * 2019-06-28 2022-08-18 Carl Wagner Compositions Comprising a Retinoid X Receptor (RXR) Agonist, a Retinoic Acid Receptor (RAR) Agonist, or a Dual RXR/RAR Agonist

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10509987A (ja) * 1996-03-14 1998-09-29 センタ インタナショナル ドゥ リシェルシェ デルマトロジーク ガルデルマ （セ イ エール デ ガルデルマ） 二環式芳香族化合物
JPH11343263A (ja) * 1998-03-31 1999-12-14 Galderma Res & Dev Snc 二芳香族化合物、および、ヒトまたは動物用医薬品並びに化粧品中へのそれらの使用
JP2001522350A (ja) * 1997-04-11 2001-11-13 シドニー キメル キャンサー センター 疾患におけるエンドセリン−１の過剰産生の阻害のためのレチノイド関連分子
JP2002513756A (ja) * 1998-05-06 2002-05-14 ガルデルマ・リサーチ・アンド・デヴェロップメント・エス・エヌ・セ メラニン産生を促進する化合物を同定するためのアッセイおよび当該アッセイにより同定されたレチノイド様化合物
JP2002515025A (ja) * 1995-10-06 2002-05-21 リガンド・ファーマシューティカルズ・インコーポレイテッド ダイマー選択的ｒｘｒモジュレーターおよびその使用方法
JP2007501800A (ja) * 2003-08-07 2007-02-01 アラーガン　インコーポレイテッド レチノイドリガンドを用いて悪液質を処置するための方法
WO2007022437A2 (en) * 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer and metabolic disorders
JP2010503615A (ja) * 2006-08-29 2010-02-04 レインナーベート リミテッド レチノイド化合物およびそれらの使用
WO2011006157A2 (en) * 2009-07-10 2011-01-13 Case Western Reserve University Rxr agonist compounds and methods
WO2011079305A1 (en) * 2009-12-23 2011-06-30 Wayne State University Therapeutic compounds
WO2011103321A1 (en) * 2010-02-19 2011-08-25 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Novel bexarotene analogs

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
DE3441788A1 (de) 1984-11-15 1986-05-15 Bayer Ag, 5090 Leverkusen Alkyl-1-cyclopropyl-1,4-dihydro-4-oxo-3-chinolincarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5962731A (en) 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
BR9306284A (pt) 1992-04-22 1998-01-13 Ligand Pharm Inc Compostos tendo seletividade pra receptores de retinóides x
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US6137002A (en) 1993-07-22 2000-10-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US6869959B1 (en) 1999-04-28 2005-03-22 Institute Of Medicinal Molecular Design Inc. Heterocyclic carboxylic acid derivatives
US6313107B1 (en) 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6291677B1 (en) 2000-08-29 2001-09-18 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6303785B1 (en) 2000-08-29 2001-10-16 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
ATE315558T1 (de) 2000-08-29 2006-02-15 Allergan Inc Verbindungen mit cytochrom p450ra1 hemmenden aktivität
CA2510298A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Acyclic pyrazole compounds
EP1541549A1 (en) 2003-12-12 2005-06-15 Exonhit Therapeutics S.A. Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
US7226951B2 (en) 2003-12-17 2007-06-05 Allergan, Inc. Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
EP1696899A1 (en) 2003-12-17 2006-09-06 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
HUE031712T2 (en) 2007-01-15 2017-08-28 Chongxi Yu Retinoids and retinoid-like compounds with positively charged water-soluble prodrugs having very high skin penetration rates
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
JP5743129B2 (ja) 2010-04-16 2015-07-01 Dic株式会社 重合性化合物を含有する液晶組成物及びそれを使用した液晶表示素子
EP2755942A2 (en) 2011-09-15 2014-07-23 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Therapeutic compounds

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515025A (ja) * 1995-10-06 2002-05-21 リガンド・ファーマシューティカルズ・インコーポレイテッド ダイマー選択的ｒｘｒモジュレーターおよびその使用方法
JPH10509987A (ja) * 1996-03-14 1998-09-29 センタ インタナショナル ドゥ リシェルシェ デルマトロジーク ガルデルマ （セ イ エール デ ガルデルマ） 二環式芳香族化合物
JP2001522350A (ja) * 1997-04-11 2001-11-13 シドニー キメル キャンサー センター 疾患におけるエンドセリン−１の過剰産生の阻害のためのレチノイド関連分子
JPH11343263A (ja) * 1998-03-31 1999-12-14 Galderma Res & Dev Snc 二芳香族化合物、および、ヒトまたは動物用医薬品並びに化粧品中へのそれらの使用
JP2002513756A (ja) * 1998-05-06 2002-05-14 ガルデルマ・リサーチ・アンド・デヴェロップメント・エス・エヌ・セ メラニン産生を促進する化合物を同定するためのアッセイおよび当該アッセイにより同定されたレチノイド様化合物
JP2007501800A (ja) * 2003-08-07 2007-02-01 アラーガン　インコーポレイテッド レチノイドリガンドを用いて悪液質を処置するための方法
WO2007022437A2 (en) * 2005-08-18 2007-02-22 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer and metabolic disorders
JP2010503615A (ja) * 2006-08-29 2010-02-04 レインナーベート リミテッド レチノイド化合物およびそれらの使用
WO2011006157A2 (en) * 2009-07-10 2011-01-13 Case Western Reserve University Rxr agonist compounds and methods
WO2011079305A1 (en) * 2009-12-23 2011-06-30 Wayne State University Therapeutic compounds
WO2011103321A1 (en) * 2010-02-19 2011-08-25 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Novel bexarotene analogs

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOEHM, MARCUS F ET AL.: "Synthesis and Structure-Activity Relationships of Novel Retinoid X Receptor-Selective Retinoids", JOURNAL OF MEDICINAL CHEMISTRY, vol. 37(18), JPN6015051010, 1994, pages 2930 - 2941, ISSN: 0003220062 *
CLAUDEL, THIERRY ET AL.: "Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X recep", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98(5), JPN6015051013, 2001, pages 2610 - 2615, ISSN: 0003220064 *
FAUL, MARGARET M. ET AL.: "Synthesis of Novel Retinoid X Receptor-Selective Retinoids", JOURNAL OF ORGANIC CHEMISTRY, vol. 66(17), JPN6015051016, 2001, pages 5772 - 5782, ISSN: 0003220065 *
GARCIA JOSE, CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, vol. V10, JPN5014010701, 1 January 2009 (2009-01-01), pages 1252 - 1259, ISSN: 0003220061 *
QING, FENG-LING ET AL.: "A Suzuki Coupling Approach to Trifluoromethyl Derivative of Targretin(LGD 1069)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 7(16), JPN6015051012, 1997, pages 2117 - 2120, ISSN: 0003220063 *
SANTIN EFREN PEREZ, JOURNAL OF MEDICINAL CHEMISTRY, vol. V52 N10, JPN5014010700, 2009, pages 3150 - 3158, ISSN: 0003220060 *
WAGNER, CARL E. ET AL.: "Modeling, Synthesis and Biological Evaluation of Potential Retinoid X Receptor(RXR) Selective Agonis", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52(19), JPN6015051017, 2009, pages 5950 - 5966, ISSN: 0003220066 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537140A (ja) * 2014-10-10 2017-12-14 ハイ フォース リサーチ リミテッド 蛍光合成レチノイド
US10759762B2 (en) 2014-10-10 2020-09-01 High Force Research Limited Fluorescent synthetic retinoids
JP7178781B2 (ja) 2014-10-10 2022-11-28 ハイ フォース リサーチ リミテッド 蛍光合成レチノイド

Also Published As

Publication number Publication date
AU2012308582B2 (en) 2016-11-24
WO2013040227A3 (en) 2013-07-25
US10391093B2 (en) 2019-08-27
EP2910549A1 (en) 2015-08-26
US20170182046A1 (en) 2017-06-29
WO2013040227A2 (en) 2013-03-21
AU2012308582A1 (en) 2014-04-03
US20140343079A1 (en) 2014-11-20
US9573906B2 (en) 2017-02-21
CA2848540A1 (en) 2013-03-21
EP2755942A2 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
JP2014527083A (ja) 治療用化合物
US6593493B1 (en) RXR modulators with improved pharmacologic profile
KR101396606B1 (ko) 신규 갑상선 호르몬 β 수용체 작동약
DE60204674T2 (de) Retinoid x rezeptormodulatoren
JP4866901B2 (ja) ３環系化合物
WO2004072046A2 (en) Quinoline derivatives and their use for modulation of lxr activity
EP2001844A2 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
WO2004072041A1 (en) Tetrahydroquinolines as agonists of liver- x receptors
US10231947B2 (en) Isochroman compounds and methods of use thereof
JP2009530322A (ja) 置換クロマノール誘導体およびそれらの使用
WO2004072042A2 (en) Quinoline derivative and their use for modulation of lxr activity
US10238655B2 (en) Dihydroindene and tetrahydronaphthalene compounds
US4965274A (en) Quinolyl methoxy compounds, processes for preparation thereof and pharmaceutical composition comprising the same
KR20160125958A (ko) Rxr 아고니스트로서의 치환 바이시클릭 헤테로아릴 화합물
WO2016140978A1 (en) Therapeutic compounds
WO2016140979A1 (en) Therapeutic compounds
US10238626B2 (en) Therapeutic compounds
WO2015109318A2 (en) Therapeutic methods
US6140362A (en) Method for inhibiting the growth of mammalian cells
DE69104481T2 (de) Imidazo[4,5-c]pyridine als paf antagonisten.
JP6199406B2 (ja) ジアシルグリセロールアシルトランスフェラーゼ阻害剤としての新規化合物
EP3459948B1 (en) Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof
JP2007509998A (ja) Ｐｐａｒ活性化剤としてのベンズ環付加された化合物
JP5789888B2 (ja) ロイコトリエン生成のベンゾイミダゾールインヒビター
JPH0324073A (ja) ジベンゾ［１，５］ジオキソシン―５―オン誘導体類、薬物におけるそれらの使用およびそれらの調製方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150703

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170316